ERBB2 and breast carcinoma: HER2 has been validated as a prognostic and predictive factor in breast cancer [1, 3], and evidence is growing that HER2 is also a driver of tumorigenesis in gastric and gastroesophageal junction cancer, with studies suggesting that HER2 amplification or overexpression is relatively frequent in this tumor type [2, 4–6].